朋友們大家好，大家早上中午晚上好 這裡是提阿非羅 現在是2025年6月9日華爾街午盤時間 我們來更新比特幣的行情 這個是比特幣的周線圖 從周線級別來看 我們發現過去這一周的周線 是非常的強勢 你可以看到它是一根十字線 好像要來救贖一下子的感覺 那麼它是把前面的低點跌破 來補充了這一帶的缺口 你會說這個缺口還有很多沒有補充完 但是我想告訴你的是 它補缺口不是它的目的 目的是把這一段追多的人 把他們的止損打掉 那麼想一下這邊有一些追多的 但是不是那麼的多 但是突破之前ALL TIME HIGH之後 在這個地方是有很多人做多的 因為大家是去做什麼 突破單對不對 往下面跌的話他的止損最低 我是認為會放在這個地方 他不可能把止損放在這裡 也不可能放在這裡，因為離得太遠了 對不對 標志性的低點就是前面這樣的一個低點 它往下面跌 把前面的低點跌破 把這樣的一些多頭的止損打掉就可以了 未必需要完全把這一帶完全補足 沒有這個必要對不對 然後就出現一個反彈 但是我從這邊看成交量好像略顯不足 感覺好像是有點強勢 但是好像中性偏強勢好不好 如果說是中性偏強勢的話 有哪樣的可能性呢 如果說是非常多的成交量往下面一跌 就非常大的成交量 ...

Summary of Verve Therapeutics (VERV) FY Conference Call - June 09, 2025 Company Overview - **Company**: Verve Therapeutics - **Focus**: Gene editing for cardiovascular disease, specifically targeting lifelong cholesterol lowering to treat coronary heart disease Key Points and Arguments 1. **HEART-two Data Announcement**: The company recently disclosed data from the HEART-two trial, which showed promising results for their gene editing therapy aimed at lowering LDL cholesterol levels [3][4] 2. **Unmet Need**: Current cholesterol-lowering therapies have a high dropout rate, with up to 50% of patients discontinuing treatment within a year. Verve aims to provide a one-time therapy that offers lifelong efficacy [5] 3. **Efficacy Results**: In the HEART-two trial, the therapy demonstrated an LDL reduction of up to 60%, with a mean reduction of 59% in the highest dose group. All patients in this group experienced over 50% lowering [8][21] 4. **Safety Profile**: The therapy was well tolerated, with only one infusion-related reaction reported among 14 patients. No significant laboratory abnormalities were observed [8][9] 5. **Durability of Effect**: The company reported that the LDL reduction was sustained at 60% two years post-infusion, supporting the vision of a one-time therapy for atherosclerotic cardiovascular disease [10][11] 6. **Comparison of Products**: The difference between the first-generation product (VRRB101) and the second-generation product (VRRB102) lies in the delivery system, which has been improved to enhance safety and efficacy [12][14] 7. **Regulatory Environment**: Recent discussions with the FDA indicate a supportive stance towards gene editing technologies, particularly those addressing chronic diseases like atherosclerosis [45][48] 8. **Market Research Findings**: Surveys indicate a significant openness among patients and physicians towards a one-time gene editing therapy, with about one-third of patients preferring this option over traditional therapies [50][53] 9. **Cost of Manufacturing**: The estimated cost to manufacture the therapy is around $3 per dose, suggesting potential for flexible pricing strategies compared to traditional gene therapies [55][56] 10. **Partnership with Eli Lilly**: The company is preparing to present data to Eli Lilly for potential opt-in for further development, which could extend Verve's cash runway [62][69] Additional Important Insights - **Dosing Strategy**: The company is shifting towards fixed dosing rather than weight-based dosing, as the therapy primarily targets the liver [24][26] - **Long-term Safety Considerations**: The company believes that the low risk of off-target effects, combined with the significant risk of untreated cardiovascular disease, will favor the adoption of their therapy [40][41] - **Future Developments**: Verve is also working on additional products targeting ANGPTL3 and Lp(a), leveraging the same delivery system as VRRB102 [64][66] This summary encapsulates the critical insights from the conference call, highlighting the company's innovative approach to gene editing in cardiovascular disease and its potential impact on patient care and market dynamics.

June 6, 2025 02:10 PM GMT Asia/Pacific Weekly Preview | Asia Pacific M Update China's Inflation to Soften; Softer Australia Business Sentiment Key Takeaways Australia China India • CPI: CPI to slow in YOY terms but to rise sequentially due to higher food prices. Japan • GDP 2nd Preliminary: Slight downward revision in real capex. Upward revision to public investment. Real GDP growth at -0.8% QoQ SAAR. Morgan Stanley Asia (Singapore) Pte.+ Derrick Y Kam Asia Economist Derrick.Kam@morganstanley.com +65 6834-8 ...

- Hey, Lex. My name is Andrew, I lead the Google Beam team, and we're going to show you a demo today. - Whoa, okay. - Okay, Lex.Here we are. All right. - This is real already.Wow. - This is real. Good to see you.This is Google Beam. - So you can feel the depth of this. - Yeah, great to meet you.- Wow. Wow. So for people, probably can't even imagine what this looks like, there's a 3D version, it looks real.You look real. - Yeah, it looks real to me, it looks real to you. - It looks like you're coming out of ...

ToplineA pessimistic prediction for Tesla sales from Goldman Sachs added further fuel to the Tesla fire, as the unraveling relationship between Tesla CEO Elon Musk and his former close ally President Donald Trump plays out publicly, accelerating Wall Street’s concerns about the increasing exposure of Tesla to Musk’s outspoken politics.Elon Musk has alienated “multiple sides of the political spectrum” from Tesla, according to one ... More prominent Wall Street analyst.AFP via Getty ImagesKey FactsIn a late T ...

Tesla, Inc.'s (NASDAQ: TSLA ) recent volatility is less an earnings issue and more an empire risk. The Musk-Trump battle shattered an illusion of political insulation that investors had long factored in.Pythia Research focuses on multi-bagger stocks, primarily in the technology sector. Our approach combines financial analysis, behavioral finance, psychology, social sciences, and alternative metrics to assess companies with high conviction and asymmetric risk-reward potential. By leveraging both traditional ...

Target (TGT -0.52%) is a passive income powerhouse with more than five decades of annual dividend raises and an enticing 4.8% yield. But even with the high payout, Target has lost investors money over the last five years while the S&P 500 (^GSPC -0.53%) has more than doubled with dividends included.Here's why Target is under pressure, and whether the dividend stock is a buy right now. Retail winners and losersRetailers like Target have been under pressure as consumers tighten spending amid inflation and eco ...

感到压力的远不止铃木一家。多家以"即时生产（Just-in-Time）"模式组织生产的日本及德国汽车制造 商，都已开始紧急排查其一级和二级供应商的库存水平。特别是那些在电动汽车（EV）和混合动力汽 车领域布局深远的企业，其核心驱动单元对高性能永磁电机的依赖度极高，而这类电机的关键材料正是 此次出口政策调整所涉及的高性能钕铁硼（NdFeB）永磁材料。 若此次零部件供应紧张的局面持续超过一个月，包括丰田、本田在内的日本车企，以及远在欧洲的大 众、宝马等，其部分高端车型和新能源车型的生产计划也可能被迫调整。影响的大小，将直接取决于各 家厂商对供应链风险的预判和备用库存的多少。 2025年6月6日，日本知名汽车制造商铃木汽车公司（Suzuki Motor Corporation）今日宣布，由于来自中 国的特定关键零部件供应短缺，公司位于日本本土的部分汽车生产线将暂时停止运营。 铃木汽车在声明中写到，部分用于汽车电子系统和发动机部件的含稀土材料的零部件未能按时到货，对 生产计划造成了直接影响。公司并未具体透露哪些车型或工厂将受到此次停产的冲击，但表示正在"尽 一切努力评估影响范围，并积极寻求替代供应方案，以期尽快恢复生 ...

文 | 中关村储能产业技术联盟 联系电话及传真：029-63913621 陕西省发展和改革委员会 2025年6月5日 附件 关于调整分时电价政策有关事项的通知（征求意见稿） 各设区市发展改革委 、 杨凌示范区发展改革局，国网陕西省电力有限公司，陕西电力交易中心，各增量配电网： 关于再次公开征求《关于调整分时电价政策有关事项的通知（征求意见稿）》意见的公告 为充分发挥分时电价信号作用，引导用户削峰填谷、促进新能源消纳及支持储能产业发展，服务新型电力系统建设和保障电力安全稳定供应，根 据《国家发展改革委关于进一步完善分时电价机制的通知》（发改价格〔2021〕1093号）精神，结合我省实际，在前期征求意见的基础上，我 们进一步修改完善了《关于调整分时电价政策有关事项的通知（征求意见稿）》，即日起再次向社会公开征求意见，欢迎社会各界人士积极建言 献策，提出宝贵意见。 公开征求意见时间截止到2025年6月12日，意见建议电子版请反馈至邮箱fgwjgc@shaanxi.gov.cn。 为充分发挥 分时 电价 信号 作用， 引导用户削峰填谷、促进新能源消纳及 支持储能产业发展， 服务新型电力系统建设 和 保障电力安全稳定 ...

Raymond James Financial (RJF) 2025 Investor Day June 05, 2025 01:30 PM ET Speaker0 Right. We might be a minute or so But we'll just go ahead and get started. First of all, thank you all for coming. Good afternoon. I'm Christy Wah, Senior Vice President of Investor Relations, and welcome to Raymond James Financial's twenty twenty five Analyst and Investor Day. We're happy that so many of you were able to join in person here in our corporate headquarters in St. Petersburg, Florida. We do really value that you ...